Kazia Prices $40M Public Offering at $15.50/ADS with Warrants, Closing Aug 31
KZIA has more than doubled off its 52-week low of $4.86 on elevated volume (5.6× avg).
Summary
Kazia priced a $40M underwritten public offering at $15.50/ADS with Series A and B warrants, closing August 31. Full warrant exercise could add $80M more, funding paxalisib development into 2029.
Key Events · Financing and Capital Events · KZIA
-
Offering Priced at $15.50/ADS
Kazia priced 2,276,800 ADSs at $15.50 each with accompanying warrants, plus 303,200 pre-funded warrants, for approximately $40 million in gross proceeds before fees.
-
Warrant Structure Adds Upside
Series A warrants (2,243,478) exercisable at $17.825 and Series B warrants (2,064,000) at $19.375 could add up to $80 million in additional gross proceeds if fully exercised.
-
Underwriting Terms
Leerink Partners and Guggenheim Securities led the deal with a 7% underwriting discount ($1.085 per ADS). BTIG, Needham, and Laidlaw acted as co-managers.
-
Closing Expected August 31
The offering is expected to close on or about August 31, 2026, subject to customary closing conditions. Officers and directors agreed to a 60-day lock-up.
Analysis · KZIA · Life Sciences
Kazia finalized terms for a $40 million underwritten offering priced at $15.50 per ADS with accompanying Series A and Series B warrants. The deal includes 2,276,800 ADSs plus pre-funded warrants and warrants to purchase up to 4.3 million additional ADSs. If all warrants are exercised, total gross proceeds could reach $120 million. The offering was priced just one day after the company reported 100% clinical benefit in its Phase 1b TNBC trial, capitalizing on the positive data momentum. The 7% underwriting discount is standard for a biotech of this size, but the warrant structure — with exercise prices at 115% and 125% of the offering price — creates meaningful potential dilution if clinical milestones are met. The deal extends Kazia's cash runway into 2029, funding the paxalisib development program across multiple cancer indications.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KZIA was trading at $13.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $155.2M. The 52-week trading range was $4.86 to $17.40. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.